Indexed on: 25 Jan '17Published on: 25 Jan '17Published in: Clinical Pharmacology & Therapeutics
We assessed the risks of immune-related adverse events with anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and anti-programmed death 1 (PD1) therapies by meta-analysis. Twenty-one studies including 11,144 patients were found. Anti-CTLA4 therapy was associated with a significantly higher risk of overall immune-related adverse events, diarrhea, immune-related colitis, pruritus and rash compared to control therapies (relative risk (RR) = 2.43, 2.10, 11.39, 3.88, 3.87, 95% confidence interval (CI) = 1.77 to 3.34, 1.52 to 2.45, 6.30 to 20.59, 2.37 to 6.37, 2.39 to 6.27, P <0.001 for all outcomes). Anti-PD1 therapy was associated with a significantly higher risk of pruritus (RR = 4.01, 95% CI = 1.97 to 8.17, P <0.001), however, did not increase the risks of other adverse events. Anti-CTLA4 and anti-PD1 therapies have distinct features of immune-related adverse events. The results of our study would aid the surveillance and management of immune-related adverse events in patients receiving these therapies. This article is protected by copyright. All rights reserved.